Epizyme Inc - Company Profile

All the sales intelligence you need on Epizyme Inc in one solution.

Save hours of research time with a comprehensive
Sales Intelligence Solution.
Understand how Epizyme Inc fits into your total
addressable market and Ideal Customer Profile.
Gain competitive edge with triggers that tell you
when and how to engage with Epizyme Inc.

Epizyme Inc: Premium Databases

Contact the team or request a demo to find out how our data can drive your business forward

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Headline	Published	Journalists
Showing 3 of 8 results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore	11 Jan 2018	Lorem
Epizyme selects CRO MedPace for Phase II registration-directed cancer basket trial of tazemetostat – source	06 Jun 2017	Alaric DeArment
Epizyme’s Phase I/II tazemetostat likely to improve NHL response rates, but draws skepticism as aggressive DLBCL option – experts	27 Jan 2017	Alaric DeArment
Oryzon eyes Nasdaq IPO YE16 or early 2017 with potential mezzanine round prior – CEO	14 Sep 2015	Natalie Morrison

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Drug Insights:

Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
Material intelligence on competitors, including breaking news
Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Gain a 360-degree view of Epizyme Inc and make more informed decisions for your business

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer